The Rise in Immunotherapy and Associated Ocular Toxicities

Anam Mazharuddin; Dan Gombos; Nagham Al-Zubidi

doi:10.1007/978-3-031-08250-4_33

The Rise in Immunotherapy and Associated Ocular Toxicities

Anam Mazharuddin, Dan Gombos, Nagham Al-Zubidi

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Immune checkpoint inhibitors (ICI) have improved prognosis in advanced malignancies but may be associated with extensive ocular immune-related adverse events (irAEs) that may be sight-threatening. Although ocular side effects account for 1% of total adverse events, they are becoming more commonplace as more people undergo treatment with ICI. This chapter aims to identify the presentation, characteristics, and management of ocular irAEs. Prompt recognition and management of ocular irAEs can improve patient care and outcomes.

Original language	English (US)
Title of host publication	Global Perspectives in Ocular Oncology
Publisher	Springer International Publishing
Pages	337-347
Number of pages	11
ISBN (Electronic)	9783031082504
ISBN (Print)	9783031082498
DOIs	https://doi.org/10.1007/978-3-031-08250-4_33
State	Published - Jan 1 2023

Keywords

Checkpoint immunotherapy
CTLA-4 inhibitors
Immune-related adverse events
Ocular oncology
PD1
PDL-1
Toxicity

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-031-08250-4_33

Cite this

@inbook{1f62c37984e84c91a770ed45fbd327a5,

title = "The Rise in Immunotherapy and Associated Ocular Toxicities",

abstract = "Immune checkpoint inhibitors (ICI) have improved prognosis in advanced malignancies but may be associated with extensive ocular immune-related adverse events (irAEs) that may be sight-threatening. Although ocular side effects account for 1% of total adverse events, they are becoming more commonplace as more people undergo treatment with ICI. This chapter aims to identify the presentation, characteristics, and management of ocular irAEs. Prompt recognition and management of ocular irAEs can improve patient care and outcomes.",

keywords = "Checkpoint immunotherapy, CTLA-4 inhibitors, Immune-related adverse events, Ocular oncology, PD1, PDL-1, Toxicity",

author = "Anam Mazharuddin and Dan Gombos and Nagham Al-Zubidi",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.",

year = "2023",

month = jan,

day = "1",

doi = "10.1007/978-3-031-08250-4_33",

language = "English (US)",

isbn = "9783031082498",

pages = "337--347",

booktitle = "Global Perspectives in Ocular Oncology",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - The Rise in Immunotherapy and Associated Ocular Toxicities

AU - Mazharuddin, Anam

AU - Gombos, Dan

AU - Al-Zubidi, Nagham

N1 - Publisher Copyright: © The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Immune checkpoint inhibitors (ICI) have improved prognosis in advanced malignancies but may be associated with extensive ocular immune-related adverse events (irAEs) that may be sight-threatening. Although ocular side effects account for 1% of total adverse events, they are becoming more commonplace as more people undergo treatment with ICI. This chapter aims to identify the presentation, characteristics, and management of ocular irAEs. Prompt recognition and management of ocular irAEs can improve patient care and outcomes.

AB - Immune checkpoint inhibitors (ICI) have improved prognosis in advanced malignancies but may be associated with extensive ocular immune-related adverse events (irAEs) that may be sight-threatening. Although ocular side effects account for 1% of total adverse events, they are becoming more commonplace as more people undergo treatment with ICI. This chapter aims to identify the presentation, characteristics, and management of ocular irAEs. Prompt recognition and management of ocular irAEs can improve patient care and outcomes.

KW - Checkpoint immunotherapy

KW - CTLA-4 inhibitors

KW - Immune-related adverse events

KW - Ocular oncology

KW - PD1

KW - PDL-1

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85158976643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85158976643&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-08250-4_33

DO - 10.1007/978-3-031-08250-4_33

M3 - Chapter

AN - SCOPUS:85158976643

SN - 9783031082498

SP - 337

EP - 347

BT - Global Perspectives in Ocular Oncology

PB - Springer International Publishing

ER -

The Rise in Immunotherapy and Associated Ocular Toxicities

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this